- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Mobile health apps could cut into state companies' market share
May 18, 2013
J.K. WallThe future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source:
smartphone apps.
MorePINCUS: State needs better life sciences startup ecosystem
May 18, 2013
Jack Pincus / Special to IBJIndiana’s life sciences sector is mostly composed of legacy companies.
MoreReport: Roche mulls sale of blood-glucose monitor business
May 17, 2013
J.K. WallRoche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over
the nearly 1,000 people working for its diabetes business in Indianapolis.
MorePANEL: Life sciences will see radically different future
May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues
of venture capital, digital health innovations and research university entrepreneurship.
MorePanel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
New seed fund aims to make Indiana a hotbed for digital health startups
May 4, 2013
J.K. WallInfuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
MoreLilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreDow AgroSciences grows sales, earnings to new heights
April 25, 2013
Mason King, Bloomberg NewsRecord sales for seeds and new crop protection products helped boost revenue 14 percent at Indianapolis-based Dow AgroSciences
LLC in its new fiscal year.
MoreLilly seeks $30.6M in tax breaks on downtown projects
April 15, 2013
Mason KingIndianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to
a new manufacturing plant and improvements to existing operations downtown.
MoreIU medical school's push to launch startups bears fruit
April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
MoreExpected revenue slump spurs Lilly to cut sales force
April 11, 2013
J.K. WallThe Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for
the loss of patent protection on two of its best-selling drugs.
MoreCity to buy key parcel for 16th Street tech corridor
April 6, 2013
Scott OlsonThe city of Indianapolis is poised to pay Citizens Energy Group $6.5 million to buy a key parcel of real estate it’s
targeting as the centerpiece of its ambitious 16 Tech project.
MoreLilly pulls back from proposals lowering takeover barriers
April 6, 2013
Greg AndrewsFortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
MoreLilly to spend $180M doubling size of Indy plant
April 2, 2013
The new investment will bring the plant's total price tag to $320 million as the pharmaceutical giant seeks to increase production
of insulin and related products.
MoreSherry Labs snapped up by Netherlands corporation
April 1, 2013
Jeff NewmanThe materials-testing business with nearly 300 employees has been acquired by Element Materials Technology. Sherry had been
owned by a group of well-connected central Indiana businessmen.
MoreProfits at center of biosimilars debate
March 18, 2013
J.K. WallHouse Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s
physician before automatically substituting a generic version of a biotech drug for a brand-name version.
MoreMedical device maker moving to Noblesville, adding jobs
March 12, 2013
Fishers-based Nexxt Spine LLC, a manufacturer of spinal implants, is consolidating operations and moving its headquarters
and manufacturing facility to Noblesville.
MoreQ&A
March 11, 2013
J.K. WallMike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug
firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s
pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
MoreLilly sues Genentech to invalidate Erbitux-related patents
March 2, 2013
Bloomberg NewsEli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments
for cancer and autoimmune diseases.
MoreDow AgroSciences wins bid to overturn pesticide guidelines
February 21, 2013
Bloomberg NewsIndianapolis-based Dow Agrosciences LLC and two other pesticide makers won a bid to overturn U.S. National Marine Fisheries
Service proposals to protect salmon when an appeals court found the agency’s decision “arbitrary and capricious.”
MoreLilly to expand partnership with diagnostic firm
February 14, 2013
IBJ Staff and Associated PressDiagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could
identify patients who could be helped by Lilly's drugs.
More'12 worst year for life sciences since 1990s
February 11, 2013
J.K. WallTo understand why Indiana’s life sciences entrepreneurs are frustrated with the flow of venture capital, look no further
than this statistic from a recent PricewaterhouseCoopers report: 2012 was the slowest year for first-time life sciences investment
since 1995.
MoreIndiana officials look to boost agriculture research
February 3, 2013
Associated PressThe state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production
by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation
Corridor.
MoreHealth care startups hungry for funds
February 2, 2013
J.K. WallFrustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create
a dedicated funding stream that could total $30 million a year.
MoreZimmer's earnings slip, but beat expectations
January 31, 2013
IBJ StaffFourth-quarter profit fell 2 percent at Zimmer Holdings Inc. due to large accounting charges, but still beat the estimates
of Wall Street analysts.
MoreBioCrossroads: Life sciences a $50B industry in Indiana
January 22, 2013
J.K. WallThe life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according
to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.